Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $389.32M |
| Gross Profit (TTM) | $300.62M |
| EBITDA | $238.10M |
| Operating Margin | 70.20% |
| Return on Equity | -575.00% |
| Return on Assets | 47.00% |
| Revenue/Share (TTM) | $2.39 |
| Book Value | $-1.61 |
| Price-to-Book | 2.59 |
| Price-to-Sales (TTM) | 1.86 |
| EV/Revenue | 2.288 |
| EV/EBITDA | 3.56 |
| Quarterly Earnings Growth (YoY) | 125.70% |
| Quarterly Revenue Growth (YoY) | 32.60% |
| Shares Outstanding | $165.24M |
| Float | $136.76M |
| % Insiders | 3.24% |
| % Institutions | 99.22% |
Volatility is currently expanding
Ironwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.
Ironwood Pharmaceuticals, Inc. ( IRWD ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Chris Stamm - Vice President of Investor Relations & Communications Thomas McCourt - CEO & Director Tammi Gaskins - Senior Vice President & Chief Commercial Officer Jeffrey Silber - Chief Medical Officer, Head of Research & Drug Development Ronald Silver - Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Jeff Ruberti - Chief Strategy Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Nicholas Mattiacci Tom Rosenfeld Presentation Operator Hello, everyone. My name is Megan, and I will be your conference operator today.
Ironwood Pharmaceuticals NASDAQ: IRWD raised its 2026 financial outlook after third-quarter sales of LINZESS reached $325 million, as improved net pricing and prescription demand supported the gastrointestinal drug's performance.
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.24 per share a year ago.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai.
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IRWD and any ticker you trade — then tracks every position and per-strategy win rate.
